Over the last two weeks we have seen a flurry of activity from U.S. District Courts across the country in the ongoing contract pharmacy disputes between pharmaceutical manufacturers and HRSA, the agency responsible for administering the 340B program. As you will recall from our previous coverage (I’ve linked to that full history of that coverage
Latest Post
More Posts
How Pfizer’s Warranty Program Gets Around Best Price?
Advocates File Suit Over Tennessee Waiver – Dissecting the Complaint
CMS Begins Internal Purge of Trump-Era Medicaid Policies
BREAKING: CMS Withdraws Letter of Agreements to States Establishing Additional Procedures for Waiver Withdrawals
CMS Releases Last Minute Letter of Agreement Establishing New Procedures for Waiver Withdraws
CMS Reneges on Historic “Grand Bargain” with Manufacturers in Tennessee Wavier Approval
CMS Approves Tennessee “Block Grant” Waiver: A Summary and Analysis from your Editors
States Can Now Keep Enhanced COVID-19 Match, Make Coverage and Benefit Changes
CMS Weighs in on FDA Importation Rule
Subscribe: Subscribe via RSS
Blogs
Firm/Org